Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 316 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment-Resistant Depression Clear all
Available No phase listed Expanded access

NRX-101 Expanded Access

NCT05779267
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
NRX-101, Transcranial Magnetic Stimulation Sham
Drug · Device
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Lamotrigine Augmentation in Resistant Depression

NCT00901407
View directory record Official record
Conditions
Unipolar Depression
Interventions
lamotrigine, placebo, paroxetine
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

NCT05624268
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 23, 2026, 9:06 AM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Not listed Not applicable Interventional

Near-Infrared Laser Stimulation for Various Neurological Conditions

NCT04489082
View directory record Official record
Conditions
Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases, Traumatic Brain Injury, Chronic Traumatic Encephalopathy
Interventions
Near Infrared Laser Stimulation
Device
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 9:06 AM EDT
Recruiting Phase 4 Interventional

Biomarker-Guided Antidepressant Selection

NCT07680140
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine, fMRI
Interventions
TMS, Ketamine
Device · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

NCT03113968
View directory record Official record
Conditions
Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine, Psychiatric Disorder, Depression, Major Depressive Disorder, Major Depressive Episode, Unipolar Depression
Interventions
electroconvulsive therapy (ECT), Ketamine
Procedure · Drug
Lead sponsor
Bo Hu
Other
Eligibility
21 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT06511908
View directory record Official record
Conditions
Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Interventions
(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

NCT01913535
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
CERC-501, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Implementation Trial of Evidence Based Practices for Mood Disorders

NCT02150577
View directory record Official record
Conditions
Bipolar Disorder, Treatment Resistant Depression
Interventions
Evidence Based Quality Improvement
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Eudora, Arkansas • Huntsville, Arkansas • Marianna, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine for Treatment Resistant Depression

NCT01407575
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

NCT04821271
View directory record Official record
Conditions
Major Depressive Disorder, Treatment-Resistant Depression, Depression
Interventions
Placebo, TS-161
Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

NCT02675556
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Allo-hMSCs, Placebo
Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 23, 2026, 9:06 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
62
States / cities
Gilbert, Arizona • Bellflower, California • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Withdrawn Phase 1 Interventional

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

NCT05268497
View directory record Official record
Conditions
Depression
Interventions
Esketamine, Cognitive Behavioral Therapy (CBT), Antidepressant
Drug · Behavioral
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ketamine Infusions for PTSD and Treatment-Resistant Depression

NCT02577250
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Interventions
Ketamine
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2Phase 3 Interventional

Neural and Antidepressant Effects of Propofol

NCT03684447
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Propofol
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

NCT00633399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918
View directory record Official record
Conditions
Depression
Interventions
Riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 23, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

NCT07553637
View directory record Official record
Conditions
Treatment-resistant Depression (TRD)
Interventions
ALTO-207, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Aripiprazole as Augmentation for TRD

NCT00174876
View directory record Official record
Conditions
Depression
Interventions
Drug Abilify
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Oct 23, 2026, 9:06 AM EDT